Erythropoiesis stimulating agents and nephroprotection: is there any room for new trials?
نویسندگان
چکیده
منابع مشابه
Anemia and heart failure: Is there still a role for erythropoiesis-stimulating agents?
A early reports of erythropoiesis-stimulating agents (ESAs) having success correcting anemia in heart failure (HF), the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) study, a large phase III trial, demonstrated that darbepoetin alfa was not able to improve clinical outcomes in patients with HF who had reduced ejection fraction and mild to moderate anemia, and indeed, it led ...
متن کاملOral Lichen Planus and Celiac Disease: is there any Relationship?
Background: Lichen planus is an autoimmune disorder and is associated with other autoimmune diseases. There is, however, little evidence of the association of oral lichen planus with celiac disease. The aim of this work was to investigate, for the first time, such an association in patients in the city of Mashhad, Iran. Methods: This case-control study was per...
متن کاملIs There any Association between Thyroid Autoimmunity and Breast Cancer?
Background: The relationship between thyroid autoimmunity and breast cancer is a challenging subject. We aimed to investigate this association in women with breast cancer. Methods: In this descriptive study, 41 women with newly diagnosed breast cancer before receiving any pharmacologic treatment and 38 healthy age-matched women were enrolled. Anti TPO Ab (anti-thyroid peroxidase antibodies), FT...
متن کاملIs there any relation between Duration of breastfeeding and anemia?
Background In the early months of life, Breastfeeding increases chance of survival, reduces recovery time after disease and mortality due to infections such as diarrhea and acute respiratory infections. However, infants who are exclusively breast-fed for more than 6 months in developing countries may be at increased risk of anemia. Therefore, the aim of study was to assess the relatio...
متن کاملNovel erythropoiesis-stimulating agents: a new era in anemia management.
Nearly two decades ago, recombinant human erythropoietin transformed the management of chronic kidney disease anemia by allowing a more sustained increase in hemoglobin than was possible by intermittent blood transfusion. The treatment was highly effective, but because of the fairly short half-life of the molecule at approximately 6 to 8 h, injections usually had to be administered two to three...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2017
ISSN: 0931-0509,1460-2385
DOI: 10.1093/ndt/gfw432